Support

Overview

Connective tissues are critical in the body: they lay under the skin and around the organs and blood vessels. Fibrosis occurs when immune cells mistakenly attack these connective tissues, causing the tissues to thicken and scar. Scarring in the lungs is called pulmonary fibrosis and is associated with other autoimmune diseases, such as rheumatoid arthritis and systemic scleroderma. Fibrosis can also be a result of damage from severe asthma.

Symptoms of pulmonary fibrosis include shortness of breath, persistent coughing, loss of appetite, fatigue, weakness and even clubbing of the fingers. Studies have shown that pulmonary fibrosis is associated with breathing in wood or metal dust, and people working in wood and metal construction and mining are at greater risk.

Our Approach

Researchers at La Jolla Institute are working to prevent the scarring in fibrosis from occurring in the first place. LJI Professor Michael Croft, Ph.D., has found a way to counteract airway wall thickening and tissue scarring. In a 2011 study, Dr. Croft found that activity of a pro-inflammatory protein called LIGHT, which is made by T cells, increases fibrosis.

Dr. Croft’s lab then discovered that when mouse models of severe asthma were treated with drugs that block LIGHT, they showed significantly less airway wall thickening and fibrosis. This finding suggests LIGHT inhibitors may be effective in reversing tissue damage in fibrosis, not only in asthmatic lungs, but in other diseases that affect the lung and/or the skin, such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, scleroderma and eczema. Drugs targeting LIGHT are now in safety trials and could be used in the future in patients with fibrosis.

Meanwhile, Dr. Croft’s lab has continued to investigate the role of LIGHT in different types of lung cells.

Related News

Nothing to display.

Labs

Jul 8, 2020
Croft Lab

Michael Croft, Ph.D., and his team focus on a number of molecules that are members of the tumor necrosis factor (TNF) and tumor necrosis factor receptor (TNFR) family.

Read More
Michael Croft, Ph.D.
Director, Scientific Affairs
Professor, Center for Autoimmunity and Inflammation